Daiichi Sankyo to close Japanese plant
This article was originally published in Scrip
Daiichi Sankyois to close a formulation plant in Osaka, Japan, operated by its Daiichi Sankyo Propharma subsidiary, as part of the restructuring of its domestic manufacturing operations. The decision followed a review of current and future capacity and product demand, and will see the facility's activities shifted to the firm's three remaining formulation sites in Japan or outsourced over the period to March 2011, when it will be closed. The Osaka site employs 130 people and makes Loxonin (loxoprofen) and Mevalotin (pravastatin) tablets, as well as an over-the-counter herbal digestive product. The impact of the move on earnings will be minor, Daiichi Sankyo said.
You may also be interested in...
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
AbbVie Japan has seen strong growth for its commercial and R&D portfolios over the past few years, but with flagship product Humira facing its first local biosimilar competition, the company is looking to brand strength and an increased oncology presence to address the challenge.